Dyne Therapeutics closes upsized public offering of 21,045,000 shares at $20.5 each
DYN•Gross proceeds and bookrunners
Gross proceeds totaled about $431.4 million, before underwriting discounts, commissions, and offering expenses.
Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James served as bookrunners.
Upsized follow-on offering closes
Dyne Therapeutics closed an upsized underwritten follow-on offering of 21,045,000 common shares at $20.5 each.
The offering included 2,745,000 shares from full exercise of the underwriters’ option to purchase additional shares.
